Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 5, Mai 2015
Page(s) 465 - 468
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20153105002
Publié en ligne 9 juin 2015
  1. Roskoski Jr R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014 ; 79 : 34–74. [CrossRef] [PubMed]
  2. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012 ; 12 : 553–563. [CrossRef] [PubMed]
  3. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008 ; 68 : 5878–5887. [CrossRef] [PubMed]
  4. Jaiswal BS, Kljavin NM, Stawiski EW, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013 ; 23 : 603–617. [CrossRef] [PubMed]
  5. Sheng Q, Liu X, Fleming E, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010 ; 17 : 298–310. [CrossRef] [PubMed]
  6. Wilson TR, Lee DY, Berry L, et al. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011 ; 20 : 158–172. [CrossRef] [PubMed]
  7. Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011 ; 3 : 99ra86. [CrossRef]
  8. Liles JS, Arnoletti JP, Kossenkov AV, et al. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. Br J Cancer 2011 ; 105 : 523–533. [CrossRef] [PubMed]
  9. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014 ; 25 : 282–302. [CrossRef] [PubMed]
  10. Mujoo K, Choi BK, Huang Z, et al. Regulation of ERBB3/HER3 signaling in cancer. Oncotarget 2014 ; 5 : 10222–10236. [PubMed]
  11. Lazrek Y, Dubreuil O, Garambois V, et al. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP and FoxO1 phosphorylation. Neoplasia 2013 ; 15 : 335–347. [CrossRef] [PubMed]
  12. Gaborit N, Abdul-Hai A, Mancini M, et al. Examination of HER3 targeting in cancer using monoclonal antibodies. Proc Natl Acad Sci USA 2015 ; 112 : 839–844. [CrossRef]
  13. Gaborit N, Larbouret C, Vallaghe J, et al. Time resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem 2011 ; 283 : 11337–11345. [CrossRef]
  14. Thomas G, Chardès T, Gaborit N, et al. HER3 expression as a predictive biomarker of the efficacy of pertuzumab in pancreatic cancer. Oncotarget 2014 ; 5 : 7138–7148. [PubMed]
  15. Larbouret C, Robert B, Navarro-Teulon I, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007 ; 13 : 3356–3362. [CrossRef] [PubMed]
  16. Larbouret C, Gaborit N, Chardès T, et al. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors down-regulation and dimers disruption. Neoplasia 2012 ; 14 : 121–130. [CrossRef] [PubMed]
  17. Larbouret C, Robert B, Bascoul-Mollevi C, et al. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol 2010 ; 21 : 98–103. [CrossRef] [PubMed]
  18. Assenat E, Azria D, Mollevi C, et al. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the therapy phase 1-2 trial. Oncotarget 2015 ; 5 (sous presse).
  19. Bodmer A, Goetsch L, Favet L, et al. Anticorps et tumeurs solides : cibles établies et pistes prometteuses. Med Sci (Paris) 2009 ; 25 : 1090–1098. [CrossRef] [EDP Sciences] [PubMed]
  20. Montagne R, Furla A, Kherrouche Z, Tulasne D. Le récepteur Met fête ses 30 ans. Med Sci (Paris) 2014 ; 30 : 864–873. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.